DOI: 10.1289/EHP11292

**Note to readers with disabilities:** *EHP* strives to ensure that all journal content is accessible to all readers. However, some figures and Supplemental Material published in *EHP* articles may not conform to 508 standards due to the complexity of the information being presented. If you need assistance accessing journal content, please contact <a href="ehp508@niehs.nih.gov">ehp508@niehs.nih.gov</a>. Our staff will work with you to assess and meet your accessibility needs within 3 working days.

## **Supplemental Material**

Estimated Transfer of Perfluoroalkyl Substances (PFAS) from Maternal Serum to Breast Milk in Women Highly Exposed from Contaminated Drinking Water: A Study in the Ronneby Mother–Child Cohort

Annelise J. Blomberg, Erika Norén, Line S. Haug, Christian Lindh, Azemira Sabaredzovic, Daniela Pineda, Kristina Jakobsson, and Christel Nielsen

## **Table of Contents**

- **Table S1.** Between-run precision for four quality control (QC) samples and between-batch precision for 164 duplicate samples, expressed as the mean and coefficient of variation (CV, %).
- **Table S2.** Study population characteristics for women who did vs. did not provide provide at least one milk sample, limited to the 211 women with a serum delivery sample and displayed as either N (%) or Mean  $\pm$  SD.
- **Table S3.** Serum PFAS concentrations at delivery for women who did vs. did not provide at least one milk sample, limited to the 211 women with a serum delivery sample and displayed as median [IQR] or N (%).
- **Table S4.** PFAS concentrations (ng/ml) by location of maternal care and sample matrix.
- **Table S5.** Serum PFHxS cutoffs for each exposure group.
- **Table S6.** Serum PFAS concentrations (ng/ml) by exposure group.
- **Table S7.** Colostrum PFAS concentrations (ng/ml) by exposure group.
- **Table S8.** Breastmilk PFAS concentrations (ng/ml) by exposure group.
- **Table S9.** The average relative contribution of each PFAS to the sum of PFAS (PFOA, PFNA, PFDA, PFUnDA, PFHxS, PFHpS and PFOS), by matrix and exposure category.

- **Table S10.** Estimated transfer efficiency (TE, 95% CI) by PFAS and lactation stage, calculated from a mixed-effects model with an interaction term between PFAS compound and lactation stage ( $N_{participants} = 126$  and  $N_{observations} = 776$ ). P-values are comparing transfer efficiency by lactation stage for each PFAS compound.
- **Table S11.** Estimated transfer efficiency (TE, 95% CI) from serum into colostrum (TE<sub>C:S</sub>) by PFAS and exposure level, calculated from a mixed-effects model with an interaction term between PFAS and exposure group (N<sub>participants</sub> = 85 and N<sub>observations</sub> = 340). P-values are for each PFAS compound and are relative to the background exposure group.
- **Table S12.** Estimated transfer efficiency (TE, 95% CI) from serum into breastmilk (TE<sub>B:S</sub>) by PFAS and exposure level, calculated from a mixed-effects model with an interaction term between PFAS and exposure group (N<sub>participants</sub> = 109 and N<sub>observations</sub> = 436). P-values are for each PFAS compound and are relative to the background exposure group.
- **Figure S1.** Exposure category cutoffs by serum PFHxS concentrations, illustrated by area (Ronneby: n = 103; Karlshamn: n = 23).
- **Figure S2.** Serum PFAS concentrations by area (Ronneby: n = 103; Karlshamn: n = 23).
- **Figure S3.** Spearman correlations across PFAS and matrices ( $N_{participants} = 126$  and  $N_{observations} = 2240$ ).
- **Figure S4.** Spearman correlations across PFAS and matrices, limited to participants in the intermediate and high exposure groups ( $N_{participants} = 101$  and  $N_{observations} = 1827$ ).
- **Figure S5.** Spearman correlations across PFAS and matrices, limited to participants in the background exposure group ( $N_{participants} = 25$  and  $N_{observations} = 239$ ). Because of the small sample size, this correlation plot excludes PFAS measurements where the majority of measurements were less than the LOQ.